{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.23"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"RP2D will be determined based on number and type of adverse event and serious adverse events, assessments of clinical laboratory values, neurotoxicity grading, and treatment discontinuation.","groups":[{"description":"In phase 1, ixazomib 1.68, 2.23, 2.97 or 3.95 mg/m\\^2, capsules, orally, once, on Days 1, 8 and 15; plus dexamethasone 40 mg, tablets, orally, once on Days 1, 8, 15 and 22; and lenalidomide 25 mg, capsules, orally, once on Days 1 through 21 of a 28-day cycle for up to 12 cycles. Cycle 13 and beyond, single agent ixazomib 1.68, 2.23, 2.97 or 3.95 mg/m\\^2, capsules, orally, once on Days 1, 8 and 15 of a 28-day cycle until disease progression or unacceptable toxicity.","id":"OG000","title":"Phase 1: Ixazomib + Lenalidomide + Dexamethasone"}],"paramType":"NUMBER","populationDescription":"All Phase 1 participants.","reportingStatus":"POSTED","timeFrame":"Until occurrence of progressive disease or unacceptable toxicity (Up to 336 days)","title":"Phase 1: Recommended Phase 2 Dose of Ixazomib Given in Combination With Lenalidomide and Low-Dose Dexamethasone","type":"PRIMARY","unitOfMeasure":"mg/m^2"}